Nyrada (ASX:NYR) said no issues were raised by the safety review committee after assessing phase one clinical trial data of its drug candidate NYR-BI03, developed to reduce brain and heart damage from brain injury and stroke, according to a Wednesday filing with the Australian bourse.

The committee assessed cumulative safety and pharmacokinetic data from the first three cohorts of the trial, the filing said.

Recruitment for the fourth cohort has been completed, the company added.

Final results from the phase one trial are expected in the third quarter of the year.